ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$34.93
+1.51%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 252.53x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 5.96x
- Price / sales
- 3349.81x
- Price / cash flow
- -31.17x
Enterprise value
- Enterprise value
- $22.2B
- EV / sales
- 2945.62x
- EV / EBITDA
- -78.86x
- EV / EBIT
- -16.24x
- Market cap
- $25.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026